About the project
The affordability of newly approved innovative health technologies (IHTs) is challenging in many health systems. Health care payers and health care industry across the European Union (EU) have explored different ways of defining payment for new products. Starting in December 2022 the HORIZON funded project ASCERTAIN , Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise iNnovative health technologies (ASCERTAIN), addresses the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe.
Guided by a conceptual framework integrating pricing, health technology assessment and reimbursement/payment, ASCERTAIN will develop open-access, easy to use, policy-supporting tools including (i) pricing models, (ii) value assessment models, and (iii) reimbursement models, which will be adaptable to country-specific conditions and patient preferences. These tools will improve transparency and accountability of decision-making, reduce uncertainty for all stakeholders, reward innovation in areas of high unmet need, accelerate access for patients, and support long-term planning and sustainability. Further, these tools will be developed, tested, and validated for three use cases, including precision cancer medicine, cell- and gene therapy, and medical devices or in vitro diagnostics.
Financing
This project has received funding from the European Union (EU) under Grant Agreement No. 101094938. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
Partners
- Erasmus Universiteit Rotterdam
- Univerzita Komenskeho V Bratislave
- Gesundheit Osterreich GmbH
- University of Oslo
- Association Internationale de la Mutualité
- Nuromedia GmbH
- European Hematology Association
- Myeloma Patients Europe
- Chino SRL
- OptiMedis
Project start - finnish
2022-2026